JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
©2021 American Association for Cancer Research..
Endocrine resistance (EnR) in advanced prostate cancer is fatal. EnR can be mediated by androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most clinically important variant. In this study, we determined proteins key to generating AR-V7, validated our findings using clinical samples, and studied splicing regulatory mechanisms in prostate cancer models. Triangulation studies identified JMJD6 as a key regulator of AR-V7, as evidenced by its upregulation with in vitro EnR, its downregulation alongside AR-V7 by bromodomain inhibition, and its identification as a top hit of a targeted siRNA screen of spliceosome-related genes. JMJD6 protein levels increased (P < 0.001) with castration resistance and were associated with higher AR-V7 levels and shorter survival (P = 0.048). JMJD6 knockdown reduced prostate cancer cell growth, AR-V7 levels, and recruitment of U2AF65 to AR pre-mRNA. Mutagenesis studies suggested that JMJD6 activity is key to the generation of AR-V7, with the catalytic machinery residing within a druggable pocket. Taken together, these data highlight the relationship between JMJD6 and AR-V7 in advanced prostate cancer and support further evaluation of JMJD6 as a therapeutic target in this disease. SIGNIFICANCE: This study identifies JMJD6 as being critical for the generation of AR-V7 in prostate cancer, where it may serve as a tractable target for therapeutic intervention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Cancer research - 81(2021), 4 vom: 15. Feb., Seite 1087-1100 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.05.2021 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/0008-5472.CAN-20-1807 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323780830 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323780830 | ||
| 003 | DE-627 | ||
| 005 | 20240214232308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-20-1807 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM323780830 | ||
| 035 | |a (NLM)33822745 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Paschalis, Alec |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2021 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2021 American Association for Cancer Research. | ||
| 520 | |a Endocrine resistance (EnR) in advanced prostate cancer is fatal. EnR can be mediated by androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most clinically important variant. In this study, we determined proteins key to generating AR-V7, validated our findings using clinical samples, and studied splicing regulatory mechanisms in prostate cancer models. Triangulation studies identified JMJD6 as a key regulator of AR-V7, as evidenced by its upregulation with in vitro EnR, its downregulation alongside AR-V7 by bromodomain inhibition, and its identification as a top hit of a targeted siRNA screen of spliceosome-related genes. JMJD6 protein levels increased (P < 0.001) with castration resistance and were associated with higher AR-V7 levels and shorter survival (P = 0.048). JMJD6 knockdown reduced prostate cancer cell growth, AR-V7 levels, and recruitment of U2AF65 to AR pre-mRNA. Mutagenesis studies suggested that JMJD6 activity is key to the generation of AR-V7, with the catalytic machinery residing within a druggable pocket. Taken together, these data highlight the relationship between JMJD6 and AR-V7 in advanced prostate cancer and support further evaluation of JMJD6 as a therapeutic target in this disease. SIGNIFICANCE: This study identifies JMJD6 as being critical for the generation of AR-V7 in prostate cancer, where it may serve as a tractable target for therapeutic intervention | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 7 | |a AR protein, human |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Protein Isoforms |2 NLM | |
| 650 | 7 | |a Receptors, Androgen |2 NLM | |
| 650 | 7 | |a Oxygenases |2 NLM | |
| 650 | 7 | |a EC 1.13.- |2 NLM | |
| 650 | 7 | |a JMJD6 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.11.- |2 NLM | |
| 650 | 7 | |a Jumonji Domain-Containing Histone Demethylases |2 NLM | |
| 650 | 7 | |a EC 1.14.11.- |2 NLM | |
| 700 | 1 | |a Welti, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Neeb, Antje J |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Figueiredo, Ines |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Riisnaes, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, Daniel Nava |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Vacas, Juan M |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Soojin |e verfasserin |4 aut | |
| 700 | 1 | |a Uo, Takuma |e verfasserin |4 aut | |
| 700 | 1 | |a Micco, Patrizio Di |e verfasserin |4 aut | |
| 700 | 1 | |a Tumber, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Islam, Md Saiful |e verfasserin |4 aut | |
| 700 | 1 | |a Moesser, Marc A |e verfasserin |4 aut | |
| 700 | 1 | |a Abboud, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Kawamura, Akane |e verfasserin |4 aut | |
| 700 | 1 | |a Gurel, Bora |e verfasserin |4 aut | |
| 700 | 1 | |a Christova, Rossitza |e verfasserin |4 aut | |
| 700 | 1 | |a Gil, Veronica S |e verfasserin |4 aut | |
| 700 | 1 | |a Buroni, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Mateus |e verfasserin |4 aut | |
| 700 | 1 | |a Miranda, Susana |e verfasserin |4 aut | |
| 700 | 1 | |a Lambros, Maryou B |e verfasserin |4 aut | |
| 700 | 1 | |a Carreira, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Tunariu, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Alimonti, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Lazikani, Bissan |e verfasserin |4 aut | |
| 700 | 1 | |a Schofield, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Plymate, Stephen R |e verfasserin |4 aut | |
| 700 | 1 | |a Sharp, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a de Bono, Johann S |e verfasserin |4 aut | |
| 700 | 0 | |a , SU2C/PCF International Prostate Cancer Dream Team |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g 81(2021), 4 vom: 15. Feb., Seite 1087-1100 |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2021 |g number:4 |g day:15 |g month:02 |g pages:1087-1100 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-20-1807 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2021 |e 4 |b 15 |c 02 |h 1087-1100 | ||